Bench to Bedside

From Bench to Bedside: New Approaches to Treating Respiratory Diseases

Wednesday • May 3, 2023 • 11:00–12:00 Noon CET • Auditorium Level 3
Moderator: Paul M. Young, Ph.D.

Inhaled Antibody Therapies: Enabling Prophylactic Protection against SARS-CoV-2 Infection with a Dual Targeting Powder Formulation
Jenny Lam
University College London
Towards The Clinical Translation of Inhaled Rifampicin for Tuberculosis
Shyamal Das
University of Otago

Discover More

Navigating New Technologies for Inhaled Product Development to Meet the Challenges of Small and Large Molecules
Mark Parry
Intertek
From Rapid Feasibility to Sustainable Products: Identifying the Right Inhalation Delivery System for Your Drug
Philip Cocks, John Patton and Keith Ung
Kindeva
Characterization of the Suitability of a Primary Cell Airway Model from the Porcine Trachea for Uptake and Permeation Studies and as a Potential Model for Mucociliary Clearance
Janik Martin
University of Applied Sciences Biberach
Evaluation of a Novel Porcine Trachea Cell Airway Model for the Screening of Excipient Toxicity used in Biopharmaceutical Inhalation Products
Rebecca Rittersberger
University of Applied Sciences Biberach
Go with the Flow: Evaluation of a Perfused Calu-3 Model Using a Micro-Physiological System for Inhaled Drug Discovery
Adeel Ahmed
University of Hertfordshire
Influence of Lung Mucus on In Vitro Dissolution and Absorption of an Inhalable Drug
Rakesh Bastola and Shyamal Das
University of Otago
CO-ORGANIZERS
CONFERENCE SUPPORTERS
↑ Back to Top